Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Masson

Pulmonary Disease Clearwater, FL Medical Doctor

NPI 1134100605 CMS profile 51441

430 Morton Plant St, Suite 405, Clearwater, FL 33756

Open in the dashboard

General payments

$5,089

252 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,350 paid to institutions, not to them · program year 2019

Through program year 2025, John Masson of Clearwater, FL is reported in the CMS Open Payments database as having received $5,089 across 252 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,350 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 67th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,179 48
2024 General $1,272 47
2023 General $820 48
2022 General $480 28
2021 General $93 5
2020 General $337 19
2019 General $910 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Masson
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to John Masson were reported at $1,179. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year John Masson Pulmonary Disease median Middle half National median
2019 $910 $377 $109–$1,340 $163
2020 $337 $230 $56–$907 $114
2021 $93 $269 $68–$1,072 $132
2022 $480 $390 $100–$1,457 $149
2023 $820 $419 $114–$1,659 $160
2024 $1,272 $476 $123–$1,818 $164
2025 $1,179 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $918 75 payments
  2. AstraZeneca Pharmaceuticals LP $536 25 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $495 23 payments
  4. Actelion Pharmaceuticals US, Inc. $458 17 payments
  5. United Therapeutics Corporation $237 9 payments
  6. Insmed, Inc. $230 11 payments
  7. Amgen Inc. $200 11 payments
  8. Inari Medical, Inc. $191 2 payments
  9. Regeneron Healthcare Solutions, Inc. $180 8 payments
  10. Abiomed $158 2 payments
  11. Other $1,487 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,922 249 payments
  2. Education $167 3 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $571 47 payments
  2. OPSUMIT $421 15 payments
  3. OFEV $400 22 payments
  4. UPTRAVI $398 14 payments
  5. NUCALA $236 18 payments
  6. Arikayce $213 10 payments
  7. TEZSPIRE Respiratory $202 9 payments
  8. TEZSPIRE Inflammation $200 11 payments
  9. CT THROMBECTOMY SYSTEM KIT $191 2 payments
  10. FLOWTRIEVER CATHETER, S $191 2 payments
  11. Other $3,511 149 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,594

Median for Pulmonary Disease: 936

Drug cost

$2,846,227

Median for Pulmonary Disease: $487,987

Branded share of claims

76.6%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 77 $985,434
Opsumit Macitentan Brand 45 $664,522
Uptravi Selexipag Brand 19 $456,358
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 289 $259,097
Xolair Omalizumab Brand 29 $112,223
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 104 $64,612
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 66 $54,801
Tadalafil Generic 25 $50,085
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 82 $43,225
Spiriva Respimat Tiotropium Bromide Brand 63 $42,356

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$165,506

Medicare's payments for the services billed

Medicare patients

611

Average age 77

Services billed

1,881

330 women, 281 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 60%
COPD 53%
Chronic kidney disease 45%
Heart failure 42%
Atrial fibrillation 39%
Depression 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $205
$205 289 —
TEZSPIRE
  • Amgen Inc. $60
  • AstraZeneca Pharmaceuticals LP $52
$113 — —
Arikayce
  • Insmed, Inc. $70
$70 — —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $65
$65 45 —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $65
$65 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record